Background
Materials and methods
Patients, study design and data collection
Data definitions
-
Chronic respiratory impairment, a patient has known or suspected chronic obstructive pulmonary disease or home ventilation therapy;
-
Congestive heart failure, a patient has chronic heart failure with marked limitation of physical activity or is unable to carry out any physical activity without chest discomfort (NYHA Classes III–IV);
-
Chronic renal failure, a patient has chronic renal failure with a creatinine clearance less than 60 ml per minute:
-
Chronic liver failure, a patient has chronic liver disease with a calculated Child Pugh score ≥ 10;
-
Immune incompetence: a patient has (a) a solid tumor which has not been resected or in remission, which is still requiring treatment or with metastasis; (b) viral immunosuppression, neoplastic disease, immunosuppressive drugs (including steroids), chemotherapy or congenital immunosuppression illness; or (c) an active hematologic neoplasm still requiring treatment;
-
Diabetes: a patient has known diabetes mellitus treated by drugs or diet.
Data management and statistical analyses
Results
Parameter (n = 2813)1 | No comorbidities | Any comorbidities* | Chronic respiratory impairment | Congestive heart failure | Chronic renal failure | Chronic liver failure | Immune incompetence | Diabetes |
---|---|---|---|---|---|---|---|---|
Patients, n (%) | 1121 (39.9) | 1692 (60.1) | 631 (22.4) | 290 (10.3) | 286 (10.2) | 112 (4.0) | 584 (20.8) | 613 (21.8) |
Male patients, n (%) | 687 (61.3) | 1042 (61.6) | 423 (67.0)* | 182 (62.8) | 190 (66.4) | 77 (68.8) | 337 (57.7) | 388 (63.3) |
Age (years), mean ± SD | 56 ± 18 | 65 ± 15* | 68 ± 13* | 72 ± 12* | 69 ± 13* | 56 ± 11 | 60 ± 16* | 67 ± 13* |
BMI (kg/m2), median (IQR) | 25.8 (23.0–29.7) | 26.1 (22.8–30.9) | 25.9 (22.9–30.1) | 26.3 (22.9–32.1) | 27.3 (24.1–32.4)* | 26.7 (22.8–30.6) | 24.9 (21.6–28.4)* | 28.1 (24.2–34.2)* |
Geo-economic areas, n (%) | ||||||||
High-income Europe | 628 (56.0) | 893 (52.8) | 357 (56.6) | 159 (54.8) | 140 (49.0)* | 54 (48.2) | 315 (54.0) | 293 (47.8)* |
High-income RW | 270 (24.1) | 476 (28.1) | 165 (26.1) | 62 (21.4) | 99 (34.6)* | 42 (37.5)* | 176 (30.1)* | 209 (34.1)* |
Middle income | 223 (19.9) | 323 (19.1) | 109 (17.3) | 69 (23.8) | 47 (16.4) | 16 (14.3) | 93 (15.9)* | 111 (18.1) |
Clinician recognition of ARDS, n (%) | ||||||||
At baseline | 373 (33.3) | 514 (30.4) | 141 (22.3)* | 70 (24.1)* | 82 (28.7) | 38 (33.9) | 217 (37.2) | 188 (30.7) |
At any time | 693 (61.8) | 1042 (61.6) | 345 (54.7)* | 154 (53.1)* | 166 (58.0) | 75 (70.0) | 410 (70.2)* | 375 (61.2) |
No longer fulfill ARDS criteria after 24 h, n (%) | 195 (17.4) | 291 (17.2) | 111 (17.6) | 58 (20.0) | 59 (20.6) | 19 (17.0) | 94 (16.1) | 98 (16.0) |
ARDS Severity, n (%) | ||||||||
Mild ARDS | 326 (29.1) | 507 (30.0) | 186 (29.5) | 96 (33.1) | 96 (33.6) | 35 (31.2) | 167 (28.6) | 181 (29.5) |
Moderate ARDS | 516 (46.0) | 822 (48.6) | 323 (51.2)* | 139 (47.9) | 142 (49.6) | 47 (42.0) | 271 (46.4) | 305 (49.8) |
Severe ARDS | 279 (24.9) | 363 (21.4)* | 122 (19.3)* | 55 (19.0)* | 48 (16.8)* | 30 (26.8) | 146 (25.0) | 127 (20.7) |
PaO2/FiO2 (mmHg) at day 1 of ARDS, mean ± SD | 157 ± 68 | 162 ± 67 | 162 ± 64 | 167 ± 67* | 172 ± 68* | 161 ± 71 | 157 ± 68 | 163 ± 67 |
pCO2 (mmHg), at day 1 of ARDS, mean ± SD | 44 ± 14 | 47 ± 16* | 54 ± 18* | 49 ± 17* | 44 ± 15 | 41 ± 12* | 44 ± 16 | 46 ± 16 |
pH, at day 1 of ARDS, mean ± SD | 7.34 ± 0.12 | 7.33 ± 0.12* | 7.32 ± 0.12* | 7.33 ± 0.11 | 7.33 ± 0.12 | 7.31 ± 0.12* | 7.34 ± 0.12 | 7.33 ± 0.13 |
Total SOFA adjusted Score, mean ± SD | ||||||||
Day 1 of AHRF | 9.3 ± 3.9 | 9.4 ± 4.2 | 8.6 ± 4.0* | 9.3 ± 3.9 | 10.3 ± 3.6* | 13.7 ± 4.1* | 9.4 ± 3.9 | 9.5 ± 4.1 |
Worst SOFA within 28 days in ICU | 10.9 ± 4.2 | 11.2 ± 4.4 | 10.2 ± 4.4* | 11.1 ± 4.3 | 11.9 ± 3.9* | 15.2 ± 3.9* | 11.5 ± 4.3* | 11.2 ± 4.4 |
Non-pulmonary SOFA adjusted score, mean ± SD | ||||||||
Day 1 of AHRF | 6.0 ± 3.9 | 6.3 ± 4.1 | 5.4 ± 4.0* | 6.2 ± 3.9 | 7.2 ± 3.7* | 10.6 ± 4.0* | 6.3 ± 4.0 | 6.3 ± 4.1 |
Worst SOFA within 28 days in ICU | 7.7 ± 4.0 | 8.1 ± 4.3* | 7.1 ± 4.3* | 8.1 ± 4.2 | 8.9 ± 3.9* | 12.0 ± 3.7* | 8.4 ± 4.2* | 8.2 ± 4.3* |
Type of admission, n (%) | ||||||||
Medical | 783 (69.9) | 1375 (81.3)* | 519 (82.3)* | 231 (79.7)* | 239 (83.6)* | 94 (83.9)* | 474 (81.2)* | 484 (79.0)* |
Post-operative | 50 (4.5) | 103 (6.1) | 36 (5.7) | 23 (7.9)* | 15 (5.2) | 10 (8.9)* | 40 (6.9)* | 36 (5.9) |
Surgical | 200 (17.8) | 193 (11.4)* | 66 (10.5)* | 32 (11.3)* | 29 (10.1)* | 6 (5.4)* | 69 (11.8)* | 80 (13.1)* |
Trauma | 88 (7.9) | 21 (1.2)* | 10 (1.6)* | 4 (1.4)* | 3 (1.0)* | 2 (1.8)* | 1 (0.2)* | 13 (2.1)* |
Number of comorbidities, n (%) | ||||||||
0 | 1121 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
1 | – | 1087 (64) | 289 (46) | 77 (27) | 63 (22) | 55 (49) | 371 (64) | 232 (38) |
2 | – | 423 (25) | 215 (34) | 111 (38) | 107 (37) | 35 (31) | 147 (25) | 231 (38) |
≥ 3 | – | 182 (11) | 127 (20) | 102 (35) | 116 (41) | 22 (20) | 66 (11) | 150 (24) |
Patient demographics
Illness severity profiles
Management of ARDS
Variable | OR | 95% CI | p |
---|---|---|---|
Age | 0.99 | 0.98–1.00 | 0.001 |
Comorbidity | |||
Chronic respiratory impairment | 0.99 | 0.79–1.24 | 0.916 |
Congestive heart failure | 1.20 | 0.89–1.62 | 0.241 |
Chronic renal failure | 1.01 | 0.75–1.38 | 0.927 |
Chronic liver failure | 0.65 | 0.41–1.03 | 0.069 |
Immune incompetence | 1.27 | 1.02–1.57 | 0.030 |
Diabetes | 1.28 | 1.03–1.57 | 0.027 |
Clinical recognition at baseline | 1.66 | 1.38–2.00 | < 0.001 |
Invasive mechanical ventilation (Ref. No.) | 1.86 | 1.37–2.52 | < 0.001 |
PaO2/FiO2 (for each 10 mmHg) | 0.95 | 0.93–0.96 | < 0.001 |
PIP | 1.03 | 1.02–1.04 | < 0.001 |
PEEP | 1.15 | 1.12–1.19 | < 0.001 |
High-income RW (vs Europe) | 0.40 | 0.32–0.50 | < 0.001 |
Middle-income countries (vs Europe) | 0.78 | 0.62–0.98 | 0.030 |
Outcomes from ARDS
Parameter | No comorbidities (n = 1121) | Any comorbidities (n = 1692)* | Chronic respiratory impairment (n = 631) | Congestive heart failure (n = 290) | Chronic renal failure (n = 286) | Chronic liver failure (n = 112) | Immune incompetence (n = 584) | Diabetes (n = 613) |
---|---|---|---|---|---|---|---|---|
Invasive ventilation-free days, median (IQR), days | ||||||||
All patients, N = 2377 | 15 (0–23) | 5 (0–23)* | 15 (0–23) | 4 (0–22)* | 0 (0–23)* | 0 (0–19)* | 0 (0–22)* | 10 (0–23)* |
Survivors, N = 1539 | 20 (13–25) | 21 (16–25)* | 22 (16–25)* | 22 (16–25) | 22 (12–25) | 22 (20–25) | 22 (16–25) | 21 (15–25) |
Duration of invasive mechanical ventilation, median (IQR), days | ||||||||
All patients, N = 2377 | 8 (4–16) | 8 (4–14) | 7 (4–14) | 8 (3–14) | 8 (4–18) | 7 (3–12)* | 8 (4–14) | 8 (4–15) |
Surviving patients, N = 1539 | 9 (4–16) | 8 (4–14)* | 7 (4–13)* | 8 (4–13) | 7 (4–17) | 7 (4–9) | 7 (4–13) | 8 (4–14) |
ARDS criteria, n (%) | ||||||||
Still present 24 h after diagnosis N = 1611 | 683 (76.1) | 928 (76.3) | 334 (75.4) | 147 (73.9) | 147 (74.2) | 64 (76.2) | 327 (77.9) | 346 (76.5) |
Resolved ARDS, N = 503 | 215 (23.9) | 288 (23.7) | 109 (24.6) | 52 (26.1) | 51 (25.8) | 20 (23.8) | 93 (22.1) | 106 (23.5) |
Duration of ICU Stay, median (IQR), days | ||||||||
All patients, N = 2813 | 11 (5–20) | 9 (5–17)* | 9 (4–16)* | 9 (4–17)* | 9 (5–20) | 8 (4–15)* | 10 (5–17)* | 10 (5–18) |
Survivors, N = 1849 | 12 (6–21) | 10 (6–18)* | 9 (5–17)* | 10 (5–18)* | 9 (6–19)* | 10 (6–16) | 10 (6–17)* | 10 (6–19) |
Duration of hospital stay, median (IQR), days | ||||||||
All patients, N = 2813 | 18 (9–35) | 16 (8–29)* | 16 (8–27)* | 14 (7–25)* | 16 (8–28)* | 10 (4–23)* | 17 (8–29)* | 16 (9–31) |
Survivors, N = 1695 | 23 (13–40) | 22 (12–38) | 19 (11–33)* | 20 (11–35)* | 22 (13–43) | 26 (16–56) | 24 (15–40) | 21 (13–40) |
ICU mortality, No. (%) | 303 (27.0) | 661 (39.1)* | 209 (33.1)* | 120 (41.4)* | 113 (39.5)* | 75 (67.0)* | 266 (45.5)* | 210 (34.3)* |
Hospital mortality, No. (%) | 347 (31.0) | 762 (45.3)* | 242 (38.7)* | 135 (46.9)* | 138 (48.4)* | 81 (72.3)* | 304 (52.4)* | 254 (41.6)* |
Limitation of life-sustaining measures, n (%) | 209 (18.6) | 493 (29.1)* | 162 (25.7)* | 87 (30.0)* | 83 (29.0)* | 49 (43.8)* | 195 (33.4)* | 158 (25.8) |
Withhold | 165 (15.4) | 408 (25.3)* | 131 (21.6)* | 70 (24.9)* | 65 (23.9)* | 43 (39.8)* | 158 (28.6)* | 142 (24.2)* |
Withdraw | 336 (20.9) | 149 (13.9)* | 113 (18.8)* | 57 (20.7)* | 64 (23.3)* | 39 (35.8)* | 129 (23.6)* | 107 (18.2)* |
Variable | OR | 95% CI | p |
---|---|---|---|
Age | 1.02 | 1.01–1.03 | < 0.001 |
BMI | 0.98 | 0.97–1.00 | 0.022 |
Comorbidity | |||
Chronic respiratory impairment | 0.98 | 0.78–1.23 | 0.839 |
Congestive heart failure | 1.42 | 1.07–1.90 | 0.016 |
Chronic renal failure | 0.97 | 0.72–1.31 | 0.858 |
Chronic liver failure | 3.35 | 2.11–5.34 | < 0.001 |
Immune incompetence | 1.96 | 1.58–2.42 | < 0.001 |
Diabetes | 0.91 | 0.73–1.15 | 0.440 |
Medical admission | 1.51 | 1.21–1.89 | < 0.001 |
No longer fulfill ARDS criteria after 24 h | 0.72 | 0.56–0.92 | 0.010 |
Adjusted non-respiratory SOFA | 1.11 | 1.08–1.14 | < 0.001 |
pH | 0.74 | 0.67–0.81 | < 0.001 |
PaO2/FiO2 | 0.98 | 0.97–1.00 | 0.013 |
paCO2 | 0.99 | 0.98–1.00 | 0.019 |
PEEP | 0.96 | 0.93–0.99 | 0.005 |
Total respiratory rate | 1.03 | 1.02–1.04 | < 0.001 |
No use of adjunctive measures within 28-day follow-up (Ref. Use of adjuncts) | 0.64 | 0.52–0.77 | < 0.001 |
High-income RW (vs Europe) | 0.71 | 0.57–0.89 | 0.003 |
Middle-income countries (vs Europe) | 1.62 | 1.29–2.04 | < 0.001 |
Variable | OR | 95% CI | p |
---|---|---|---|
Age | 1.03 | 1.02–1.03 | < 0.001 |
BMI | 0.98 | 0.96–0.99 | < 0.001 |
Comorbidity | |||
Chronic respiratory impairment | 0.94 | 0.74–1.19 | 0.604 |
Congestive heart failure | 1.25 | 0.92–1.70 | 0.156 |
Chronic renal failure | 1.00 | 0.73–1.37 | 0.988 |
Chronic liver failure | 2.22 | 1.40–3.53 | 0.001 |
Immune incompetence | 1.58 | 1.25–1.99 | < 0.001 |
Diabetes | 0.97 | 0.76–1.24 | 0.819 |
Medical admission | 1.37 | 1.07–1.76 | 0.013 |
Adjusted non-respiratory SOFA | 1.05 | 1.03–1.08 | < 0.001 |
pH | 0.88 | 0.80–0.95 | 0.002 |
PEEP | 0.95 | 0.92–0.98 | 0.004 |
Total RR | 1.04 | 1.02–1.05 | < 0.001 |
High-income RW (vs Europe) | 0.72 | 0.55–0.94 | 0.016 |
Middle-income countries (vs Europe) | 0.61 | 0.45–0.81 | 0.001 |
Number of beds per physician | 1.03 | 1.01–1.06 | 0.001 |